Keyphrases
Prostate Cancer
96%
Statins
55%
Radical Prostatectomy
44%
Androgen Deprivation Therapy
39%
Prostate Cancer Progression
37%
Statin Use
37%
Aldosterone
37%
Prostate Cancer Risk
33%
Adverse Effects
26%
Aldosterone Synthesis
26%
Atorvastatin
25%
CYP11B2
25%
Disease-specific Mortality
25%
Sexual Behavior
24%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
24%
High Risk
23%
Large Intestine
22%
Lipid Metabolism
21%
Aldosterone Synthase
20%
Randomized Clinical Trial
20%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
20%
Erectile Dysfunction Treatment
18%
Transdermal Estradiol
18%
Common pitfalls
18%
Breast Cancer
18%
Bone Tumor
18%
Fadrozole
18%
Enzalutamide Resistance
18%
Rat Colon
18%
MiR-26a
18%
Cholesterol Levels
18%
Lipids
18%
Enhancement Effect
18%
Endopelvic Fascia
18%
Postoperative Incontinence
18%
Polygenic Risk Score
18%
Meta-analysis
18%
National Cohort Study
18%
Non-associated
18%
Cardiovascular Disease
18%
Tumor Targeting
18%
Targeting Mechanism
18%
Cancer-specific
18%
Tumor Immune Environment
18%
Randomized Double-blind
18%
Pharmacoepidemiology
18%
Systematic Meta-analysis
18%
Finnish Men
18%
Phase III Clinical Trial
18%
Testing Effect
18%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Statin (Protein)
49%
Androgen
39%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
37%
Atorvastatin
28%
Cohort Study
21%
Castration Resistant Prostate Cancer
20%
Placebo
20%
Cancer Mortality
19%
Bone Tumor
18%
Fadrozole
18%
Bone Cancer
18%
Aldosterone Synthase
18%
Replacement Therapy
18%
Diethylstilbestrol
18%
Enzalutamide
18%
Cancer Growth
18%
Erectile Dysfunction
18%
Cancer Incidence
18%
Transdermal
18%
Clinical Study
18%
Breast Cancer
18%
Aldosterone
18%
Cardiovascular Disease
18%
Thymidine Kinase 1
18%
Diseases
18%
Overall Survival
12%
Dextran Sulfate
10%
Hypocholesterolemic Agent
10%
Malignant Neoplasm
8%
Enteritis
8%
Biological Marker
7%
Androgen Receptor
6%
Antidiabetic Agent
6%
Prostate Specific Antigen
6%
Recurrent Disease
5%
Tolerability
5%
Western Blot
5%
Medicine and Dentistry
Prostate Cancer
83%
Cancer Growth
37%
Aldosterone
37%
Aldosterone Synthase
26%
Colon
22%
Clinical Study
21%
Neoplasm
21%
Lipid Metabolism
21%
Large Intestine
21%
Randomized Clinical Trial
20%
Androgen Deprivation Therapy
18%
Fadrozole
18%
Prostatectomy
18%
Fascia
18%
Meta-Analysis
18%
Atorvastatin
18%
Systematic Review
18%
Incontinence
18%
Immunity
18%
Thymidine Kinase 1
18%
Adverse Effect
18%
Statin
13%
Overall Survival
12%
Dextran Sulfate
10%
Placebo
10%
Enteritis
8%
Surgical Technique
8%
Urine Incontinence
8%
Urinary System
8%
Enuresis
8%
Single Nucleotide Polymorphism
7%
Meta-Regression
7%
Western Blot
6%
Androgen Receptor
6%
Hazard Ratio
6%
Prostate Specific Antigen
6%
Solid Malignant Neoplasm
5%
Cancer Cell
5%
Arm
5%
Recurrent Disease
5%
Immunocompetent Cell
5%
Malignant Neoplasm
5%
Treatment Response
5%